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Impaired DNA-binding affinity of 
novel PAX6 mutations
Seowhang Lee1,7, Seung-Han Lee2,7, Hwan Heo3, Eun Hye oh4, Jin-Hong Shin  4, 
Hyang-Sook Kim4, Jae-Ho Jung5, Seo Young choi6, Kwang-Dong choi6, Hakbong Lee1, 
Changwook Lee1* & Jae-Hwan choi4*
Mutations in human PAX6 gene are associated with various congenital eye malformations including 
aniridia, foveal hypoplasia, and congenital nystagmus. These various phenotypes may depend on 
the mutation spectrums that can affect DNA-binding affinity, although this hypothesis is debatable. 
We screened PAX6 mutations in two unrelated patients with congenital nystagmus, and measured 
DNA-binding affinity through isothermal titration calorimetry (ITC). To elucidate phenotypic 
differences according to DNA-binding affinity, we also compared DNA-binding affinity among the 
previously reported PAX6 missense mutations within the linker region between two subdomains of 
the paired domain (PD). We identified two novel mutations of PAX6 gene: c.214 G > T (p.Gly72Cys) 
and c.249_250delinsCGC (p.Val84Alafs*8). Both were located within the linker region between the 
two subdomains of the PD. ITC measurement revealed that the mutation p.Val84Alafs*8 had no DNA-
binding affinity, while the p.Gly72Cys mutation showed a decreased binding affinity (Kd = 0.58 μM) by 
approximately 1.4 times compared to the wild type-PAX6 (Kd = 0.41 μM). We also found that there was 
no close relationship between DNA-binding affinity and phenotypic differences. Our results suggest 
that the DNA-binding affinity alone might be insufficient to determine PAX6-related phenotypes, and 
that other modifier genes or environmental factors might affect phenotypes of the PAX6 gene.
The PAX6 gene (MIM 607108) is a highly conserved gene to play an essential role in eye development1,2. It was iden-
tified as a candidate gene for congenital aniridia by positional cloning, and acts as a “master control” gene for nor-
mal oculogenesis by encoding a transcriptional regulatory protein2,3. The protein has two DNA-binding domains, 
a paired domain (PD) and a homeodomain, that recognize different DNA-binding sequences of target genes4–8.
To date, more than 400 heterozygous mutations within the PAX6 gene have been identified in the Human 
PAX6 Allelic Variant Database2,9–11. Classically, PAX6 mutation is associated with an aniridia, but may also causes 
a variety of non-aniridia phenotypes such as microcornea, foveal hypoplasia, keratitis, and optic nerve malforma-
tions12–19. According to a comprehensive review of PAX6 mutations, phenotypes have relied mostly on mutation 
spectrums and distributions; aniridia is typically caused by truncating mutations, while non-aniridia is generally 
caused by missense mutations2,11,20. This has been explained by differences in the DNA-binding affinity and tran-
scriptional activation, but this hypothesis is debatable21–24.
We report two novel PAX6 mutations associated with infantile nystagmus syndrome (INS). We also analyzed 
the DNA-binding affinity of mutant PAX6 to elucidate the relationship between DNA-binding affinity and phe-
notypic differences.
Results
Clinical characteristics. Detailed ophthalmic and oculomotor findings are described in Table 1. Case 
1 (P1-MSH, II-4, Fig. 1A) was a 5-year-old male with poor visual acuity and congenital nystagmus. Slit lamp 
examination with anterior segment photography showed a corectopia with normal-appearing iris and no 
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transillumination (Fig. 2A), however anterior segment optical coherence tomography (AS-OCT) revealed a gen-
eralized iris stromal hypoplasia (Fig. 2B). In addition, there was a lack of contraction furrows and crypts on the 
iris ciliary zone and flattening of collarette pupillary zone. Posterior segment OCT (PS-OCT) showed foveal 






(OD/OS) Iris anomaly Strabismus Nystagmus OCT Other features
P1-MSH
   I-2 F/42
c.214 G > T Ex 6 (PD) p.Gly72Cys
0.3/0.3 Iris hypoplasia XT HJ (PAN) FH (G4) cataract, corectopia
   II-1 F/17 0.2/0.3 Iris hypoplasia (—) HJ (PAN) FH (G4) cataract, corectopia
   II-2 F/15 0.2/0.3 Iris hypoplasia XT HJ (PAN) FH (G4), ONH corectopia
   II-4 M/5 0.2/0.2 Iris hypoplasia (—) HJ FH (G4) corectopia
P2-AJY
   II-1 F/14 c.249_250delinsCGC Ex 6 (PD) p.Val84Alafs*8 0.1/3m0.1 Iris hypoplasia XT HJ FH (G4) corectopia, corneal dystrophy
Table 1. Clinical and genetic characteristics of two families with PAX6 mutation. BCVA = best-corrected 
visual acuity; Ex = exon; F = female; FH = foveal hypoplasia; G4 = grade 4; HJ = horizontal jerky; M = male; 
OCT = optical coherence tomography; ONH = optic nerve head hypoplasia; PD = paired-box domain; 
PAN = periodic alternating nystagmus; XT = exotropia.
Figure 1. Pedigree of the patients and sequencing results of PAX6 gene. Pedigree (A) and sequencing result (B) 
of case 1. Solid symbols (squares = males, circles = females) indicate clinically affected individuals; and open 
symbols, unaffected individuals. The proband (II-4) is indicated by an arrow. DNA sequences for an unaffected 
member (II-3, upper) and the proband (II-4, bottom). The chromatograms of PAX6 genomic sequences reveals 
a heterozygous missense mutation c.214 G > T of exon 6 in the proband. This is predicted to result in the 
substitution of the highly conserved glycine by cysteine at position 72. Pedigree (C) and sequencing result (D) 
of case 2. The proband (II-1) is indicated by an arrow. In the proband, the chromatograms shows a deletion 
of nucleotides c.249 to c.250 (TG), replaced by nucleotides CGC in exon 6. This mutation causes a premature 
termination codon 8 amino acids downstream.
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phenotypical characteristics including presenile cataracts in two (I-2 and II-1), exotropia in two (I-2 and II-2), 
and optic nerve head hypoplasia in one (II-2). Case 2 (P2-AJY, II-1, Fig. 1C) was a 14-year-old female with poor 
visual acuity, congenital nystagmus and exotropia. She also had a peripheral corneal dystrophy and corectopia 
without transillumination on slit lamp examination (Fig. 2D). AS-OCT demonstrated iris anomalies including 
a lack of contraction furrows and crypts on the iris ciliary zone and flattening of the collarette pupillary zone 
(Fig. 2E). Foveal hypoplasia of grade 4 was observed in PS-OCT (Fig. 2F). Her mother and younger sister were 
clinically normal for both eyes.
Mutation analysis. After variant filtering, annotation, and interpretation, we identified novel mutations of 
PAX6 (NM_001258462.1) in each of the two patients. These two mutations were absent in 150 normal controls 
and all public databases of dbSNP, ExAC, 1000 Genomes Project, and KRGDB. Three rare variants were detected 
in other INS-associated genes (c.8192 T > C and c.5825 G > A in ALMS1; c.5593 C > T in ABCA4), but they were 
unlikely to be pathogenic based on a heterozygous mutation, in silico prediction, the public database, and the 
clinical phenotype (see Supplementary Tables S1 and S2).
Case 1 had a heterozygous missense mutation c.214 G > T (p.Gly72Cys) in exon 6, which was predicted to 
result in substitution of the highly conserved glycine by cysteine at position 72 within the linker region between 
two subdomains of the PD (Fig. 1B). The mutation showed deleterious effect by all prediction tools, and 
co-segregated with disease phenotype in all affected family members (I-2, II-1 and II-2).
Case 2 had a heterozygous mutation c.249_250delinsCGC (p.Val84Alafs*8) in exon 6, resulting in a change 
of valine into alanine at position 84 and subsequently leading to a premature termination codon 8 amino acids 
downstream in the C-terminal subdomain of the PD (Fig. 1D). This mutation was not detected in unaffected 
family members (I-2 and II-2).
DNA-binding affinities of PAX6 mutations. DNA-binding affinities of the PAX6 mutations are summa-
rized in Table 2.
Based on the crystal structure of PAX6 bound to DNA, the PD adopts two helix-turn-helix motifs (PAI and 
RED subdomain) that are connected by an extended loop comprising residues 62–83 (Fig. 3A)21. Each subdomain 
binds to the distinctive major groove of DNA in a bipartite manner, whereas the linker loop binds to the minor 
Figure 2. Clinical characteristics of the patients. (A–C) In case 1, anterior segment photography of the right 
eye (A) shows no obvious iris anomaly except for minimal nasally displaced pupil. Anterior segment optical 
coherence tomography (AS-OCT) (B) reveals a generalized iris stromal hypoplasia (white asterisk) with a 
lack of contraction furrows and crypts on the iris ciliary zone (white arrow head) and flattening of collarette 
pupillary zone (red circle). Posterior segment OCT (PS-OCT) (C) shows the absence of foveal pit (white arrow). 
(D–F) In case 2, anterior segment photography of the left eye (D) reveals nasally displaced pupil with iris 
ectropion uvea (white asterisk) and peripheral corneal dystrophy (black arrow). AS-OCT (E) shows a lack of 
contraction furrows and crypts on the iris ciliary zone (white arrow head) and flattening of collarette pupillary 
zone (red circle). There is the absence of foveal pit in PS-OCT (F, white arrow).
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groove of the DNA and its flexibility assists the PD to accommodate appropriately to major grooves of its target 
DNA (Fig. 3B). To examine if these identified mutations might affect DNA binding, we measured the binding 
affinity between PAX6 and its target DNA using an ITC. For this experiment, DNA fragment (Pax6 binding 
sequence, referred to as “P6B”, see Supplementary Fig. S1) used for crystallization was prepared as described pre-
viously21. As shown in Fig. 3C, wild type PAX6 (WT-PAX6) could bind to the P6B with an affinity of around 0.41 
μM dissociation constant (Kd) value. Interestingly, each PAI subdomain with linker or RED subdomain alone did 
not bind to the DNA in solution, suggesting that both subdomains might be essentially required to interact with 
the DNA (Fig. 3D,E). The result of PAI subdomain with linker showed that the mutation p.Val84Alafs*8 of case 
2 had no DNA binding affinity (Fig. 3D).
Next, we analyzed p.Gly72Cys (case 1 in this study), p.Gly72Ser25 and p.Gly73Asp26 mutations associated with 
iris anomaly within the linker region between the two subdomains of the PD. According to the crystal structure, 
p.Gly72 located in the center of linker could support the flexibility in this linker region (Fig. 4A). Nevertheless, 
the p.Gly72Cys mutant identified in this study could bind to the P6B with an affinity of 0.58 μM, suggesting that 
the DNA binding was mildly impaired in p.Gly72Cys mutation compared to that of WT-PAX6 (Fig. 4B). And two 
successive glycine residues (p.Gly72 and p.Gly73) located in the center of linker could support the flexibility in 
this linker region. Thus, the p.Gly72Ser mutation showed a decreased binding affinity by 2.8 times (Kd = 1.2 μM) 
compared to WT-PAX6, and had more meaningful effect than the p.Gly72Cys mutation (Table 2, Fig. 4B). We 
assumed that even if the mutation might somehow restrict the flexibility of the linker, p.Gly73 could still offer 
flexibility to the linker. Therefore, the linker could maintain a flexibility and retain its ability to interact with DNA. 
With regard to the pGly73Asp mutation, a previous study using EMSA has revealed that this mutation leads to 
complete loss of its binding ability for CD19 A-ins DNA sequences (see Supplementary Fig. S1) known as another 
target sequence of PAX626. Indeed, the binding affinity of p.Gly73Asp mutation for CD19 A-ins was undetectable 
in our ITC measurement either (see Supplementary Fig. S2 and Table S3). Whereas, the binding affinity of the 
mutant for the P6B (Kd = 0.489 μM, Fig. 4B) or P6CON (Kd = 0.961 μM, see Supplementary Fig. S2 and Table S3) 
was unaffected compared to the WT.
Finally, we measured DNA-binding affinities of missense mutations (p.Gly64Val23, p.Ser74Gly27, p.Pro76Arg24) 
associated with non-aniridia phenotype within the linker region between the two subdomains of the PD. Previous 
in silico modeling data have suggested that the p.Ser74Gly mutation can result in the absence of side chain of 
the residue, and therefore might perturb the DNA binding properties of PAX627. However, p.Ser74Gly and 
p.Pro76Arg mutations mildly impaired DNA binding (p.Ser74Gly: Kd = 0.70 μM; p.Pro76Arg: Kd = 0.74 μM) 
although the side chain of p.Ser74 and p.Pro76 residue made an H-bond and hydrophobic contact with deoxy-
ribose from the minor groove, respectively (Table 2, Fig. 4B)21. The p.Gly64 residue was not directly involved in 
the DNA structure by crystal structure (Fig. 4A). However, it formed a van der Waals stack with p.Tyr60 known 
to play an important role in adopting a three-helix bundle structure in PAI subdomain21. Therefore, the change of 
glycine into valine might cause steric hindrance in this region, thus affecting the stability of PAX6 and eventually 
hindering DNA binding. Consistent with this hypothesis, the p.Gly64Val mutation showed a 6-fold decreased 
binding affinity compared to WT-PAX6 (Table 2, Fig. 4B). Unlike our data, a previous study using EMSA has 
shown that p.Gly64Val mutation exhibited an enhanced binding affinity to P6CON, a promoter sequence specifi-
cally recognized by PAX628. To analyze if the mutation could exhibit different effects depending on distinct target 
DNA promoters, we also measured binding affinity of p.Gly64Val mutation for both P6CON and CD19A-ins 
DNA sequences (see Supplementary Fig. S1) known as target sequences of PAX628,29. Consistent with our data, 
the p.Gly64Val mutation showed a decreased binding affinity for both P6CON and CD19 A-ins by 1.4 times and 
2.3 times, respectively (see Supplementary Fig. S2 and Tables S3 and S4).
Discussion
We identified two novel mutations within the PAX6 gene in patients with iris hypoplasia and INS. One was a mis-
sense mutation (c.214 G > T, p.Gly72Cys) and the other was a truncating mutation (c.249_250delinsCGC, p.Val-
84Alafs*8). Both were located within the linker region between two subdomains of the PD, leading to impaired 
DNA-binding affinity as demonstrated by ITC measurement.
The PAX6 gene maps to chromosome 11p13 and contains 14 exons including an alternatively spliced exon 5a2. 
It encodes a transcriptional regulator which plays an important role in oculogenesis and other developmental 
Mutation Iris anomaly Kd (μM) N △H (kJ/mol)
T△S 
(kJ/mol) reference
WT WT 0.411 ± 0.068 0.972 ± 0.012 −187 ± 4.61 −150 (—)
p.Gly72Cys iris hypoplasia 0.579 ± 0.370 0.762 ± 0.044 −125 ± 13.2 −89.5 this study
p.Val84Alafs*8 iris hypoplasia no binding — — — this study
p.Gly64Val normal iris 2.520 ± 1.020 0.751 ± 0.043 −195 ± 24.2 −163 23
p.Gly72Ser iris hypoplasia 1.200 ± 0.130 0.728 ± 0.009 −115 ± 3.24 −80.8 25
p.Gly73Asp aniridia 0.489 ± 0.128 0.590 ± 0.014 −83.3 ± 3.59 −47.3 26
p.Ser74Gly normal iris 0.699 ± 0.180 0.831 ± 0.019 −106 ± 5.18 −70.8 27
p.Pro76Arg normal iris 0.740 ± 0.093 0.712 ± 0.008 −111 ± 2.82 −75.8 24
Table 2. DNA (P6B) binding affinities of PAX6 mutations. Kd is dissociation constant in equilibrium state; N, 
stoichiometry indicates the ratio of ligand-to-macromolecule binding; ΔH, enthalpy is indication of changes 
in hydrogen and van der Waals bonding; TΔS, entropy is indication of changes in hydrophobic interaction and 
conformational changes.
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processes4–8. The PAX6 protein consists of the PD, the homeodomain, and the proline/serine/threonine-rich 
transactivation domain8. The PD is composed of two distinct DNA-binding subdomains: the N-terminal sub-
domain (PAI) and the C-terminal subdomain (RED) (Fig. 3A). Since the PD and homeodomain recognize 
different DNA-binding sequences, the PAX6 protein can have the diversity in DNA sequence recognition pat-
tern of a variety of target genes21,27. In humans, PAX6 mutations are associated with a variety of congenital eye 
malformations2,11–20. The classic phenotype is aniridia characterized by congenital absence of the iris. It is often 
accompanied by congenital anomalies of the cornea, lens, retina and optic nerve12–15. PAX6 mutations also cause 
various non-aniridia phenotypes without iris abnormalities such as microcornea, foveal hypoplasia, keratitis, 
Figure 3. Structure and DNA binding affinity of the paired domain of PAX6. (A) Schematic diagram showing 
a primary structure of the paired domain (PD) of PAX6. The PD of PAX6 comprises N-terminal PAI and 
C-terminal RED subdomains, and a linker between the two subdomains. Sequences corresponding to the linker 
among the PAX paralogue proteins, PAX1 to 6 are aligned to highlight their conservation. Missense mutations 
found by previous and this study are labeled with black arrows. DNA duplex sequence (P6B) used for ITC 
experiments is shown below. (B) The structure of PAX6 (green) bound to DNA (orange) (PDB ID: 6PAX). (C) 
ITC measurement between wild-type PAX6 PD (reside: 4–136) and its target DNA (See methods for details). 
(D,E) ITC measurement of truncated PAX6 (D; residues 4–83, E; residues 84–136). The results show that each 
PAI subdomain with linker or RED subdomain alone does not bind to the DNA in solution. The upper panels 
shows the raw ITC data for injection of target DNA into the sample cell containing PAX6. The reaction heat of 
DNA and protein binding was represented as differential power (DP) between the reference and sample cells to 
maintain a same temperature. Molar ratio calculated by DNA: protein binding concentration and integrated as 
shown in the bottom panels. Experimental data indicated with solid dots and fitted in a binding curve using a 
one-site binding model.
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and optic nerve malformations16–19. The aniridia phenotype is predominantly associated with truncating muta-
tions that result in a premature termination codon (PTC), while missense mutations usually lead to non-aniridia 
phenotypes2,11,20. Since missense mutations causing non-aniridia phenotypes are mostly located in the PD, par-
tially impaired DNA-binding affinity has been proposed as a major mechanism of non-aniridia phenotypes21–24. 
Figure 4. DNA binding affinity for PAX6 missense mutations within the linker region between the two 
subdomains of the PD. (A) Close-up views show the interactions between PAX6 and its target DNA. Color scheme 
is the same as Fig. 3B. Oxygen and nitrogen atoms are colored red and blue, respectively. The yellow dotted lines 
indicate intermolecular hydrogen bonds between PAX6 and DNA. (B) ITC measurements of PAX6 missense 
mutations for DNA. Although all missense mutations show the impaired DNA-binding affinity compared to the 
wild-type PAX6, some (G72C, G73D, and S74G) have no dramatic effect for the DNA-binding affinity.
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Indeed, previous functional assays have demonstrated that the p.Ile87Arg mutation with no DNA-binding affinity 
can result in complete aniridia, while the p.Arg26Gly mutation with the relatively less impaired DNA-binding 
affinity can lead to a non-aniridia phenotype by a hypomorphic allele22.
However, this genotype-phenotype correlation of PAX6 mutations remains controversial. Some truncating 
mutations have been associated with the non-aniridia phenotypes such as autosomal dominant keratitis, optic 
nerve hypoplasia (ONH), and congenital cataract16,18,30. On the contrary, total aniridia has been reported in mis-
sense mutations22,31,32. Sometimes, the same mutation can result in various phenotypes ranging from normal iris 
to complete absence of the iris among the same family members19,31. In our study, patients showed similar phe-
notypes including iris hypoplasia, INS, and foveal hypoplasia regardless of the mutation spectrum. In particular, 
the iris had an almost normal appearance when viewed through slit lamp biomicroscopy, but abnormal changes 
in the iris architecture could be detected by AS-OCT. This may imply that AS-OCT is the best tool to identify iris 
abnormalities associated with PAX6 mutations, and caution must be taken when drawing conclusions about a 
non-aniridia phenotype without using AS-OCT33.
In addition, ITC measurement in our study did not show any relationship between DNA-binding affinity 
and phenotypic differences. DNA-binding affinities of previously reported missense mutations (p.Gly64Val23, 
p.Ser74Gly27, p.Pro76Arg24) with normal iris phenotype were more impaired than those of p.Gly72Cys (case 1 in 
our study) and p.Gly73Asp26, both being associated with iris anomalies. The p.Gly64Val mutation associated with 
non-aniridia phenotype showed the most impaired DNA-binding affinity. A family with p.Ser74Gly mutation had 
additional intellectual disabilities and epilepsy despite mildly impaired DNA-binding affinity27. The truncating 
mutation of case 2 showed a failure of DNA-binding in solution, although the patient had a full iris with abnormal 
architecture, rather than total absence of the iris. These observations suggest that the DNA-binding affinity alone 
is not sufficient to determine PAX6-related phenotypes, and other modifier genes or environmental factors might 
affect these phenotypes31. Various co-activators such as Sox2 and Maf, and co-repressors such as Smad3 and 
Nkx6.1 might play important roles in the expression of downstream targets of PAX634–36. One report has revealed 
a suppression failure of the PAX2 promoter activity as well as impairment of the transcriptional activation poten-
tial of PAX6 in a patient with bilateral ONH caused by a non-sense mutation18. The authors speculated that PAX2 
and PAX6 might cooperate in optic-nerve formation and that a failure of the PAX6-PAX2 regulatory circuit might 
affect phenotypic manifestations. In addition, a recent study has revealed that PAX6 nuclear localization signal 
(NLS) sequence exists in the PD, especially residues 48 to 83, including residues studied in the present study37. 
Therefore, future study is needed to address whether mutations within this region could prevent PAX6 from 
translocating into the nucleus, resulting in phenotypic differences.
In this study, we measured the binding affinity between PAX6 and its various target DNA fragments using 
ITC, and confirmed that PAX6 had a comparable binding affinity for the DNA. ITC is a physical technique used 
to determine thermodynamic parameters of interactions in solution, and widely used to study DNA-binding 
affinity38. ITC measurement could produce quite accurate binding constants that can be used to exactly compare 
molecular affinities among molecules with a fine distinction. Actually, differences in binding affinities among 
PAX6 mutants produced by ITC measurements were too small to be distinguished by other traditional studies 
such as EMSA. Interestingly, we found that PAX6 mutation showed distinctive effects depending on target DNA 
sequences. For example, the p.Gly73Asp mutation showed no binding affinity for the promoter DNA sequence 
required for the expression of B-cell surface protein CD19 (see Supplementary Table S3), but mild effects on P6B 
(Table 2) and P6CON (see Supplementary Table S4) promoters for ζ-crystallin expression. We assume that the use 
of different target DNA sequence might lead to conflicting results for DNA-binding affinity compared to a pre-
vious study using EMSA. It has been reported that PAX6 has consensus DNA sequences to be recognized. Based 
on PAX6 crystal structure, PAI and RED subdomains of PAX6 might interact with consensus “TTCACGC” and 
“TG” sequences, respectively. The linker loop between PAI and RED can specifically bind to consensus “ATGA” 
sequence21. Since P6B and P6CON have similar DNA sequence to be recognized by PAX6, effects caused by PAX6 
mutation could be quite similar to each other (Fig. 4B, and see Supplementary Fig. S2, and Table S4). However, 
the DNA sequence for CD19 A-ins is different from that of P6B or P6CON except six consensus sequences 
(CAC-G-GT). Since we have primarily focused on the analysis of PAX6-P6B/P6CON complex involved in the 
expression of ζ-crystallin, we believe that biochemical study of PAX6-P6B would be more reasonable to under-
stand the function of PAX6 mutation. Nevertheless, to gain further insight of structure and function relationship 
of PAX6 and its target promoter, complex structures of PAX6 bound to P6CON or CD19 A-ins may be needed.
In conclusion, we identified two novel mutations of PAX6 gene in patients with iris hypoplasia and INS: 
c.214 G > T (p.Gly72Cys) and c.249_250delinsCGC (p.Val84Alafs*8) in exon 6. Using ITC measurement, we 
demonstrated that the mutation p.Val84Alafs*8 had no DNA binding affinity, while the p.Gly72Cys mutation 
showed a decreased binding affinity by approximately 1.4 times compared to the wild type-PAX6. We also found 
that there was no close relationship between DNA-binding affinity and phenotypic differences, suggesting that the 
DNA-binding affinity alone might not be sufficient to determine PAX6-related phenotypes, and other modifier 
genes or environmental factors might affect phenotypes of the PAX6 gene.
Methods
Subjects and clinical assessment. Two patients were referred to the Neuro-ophthalmology Clinic 
of Pusan National University Yangsan Hospital for evaluation of infantile nystagmus syndrome (INS). Case 1 
(P1-MSD) had a family history of INS consisting of four clinically affected and two unaffected members (Fig. 1A), 
and case 2 (P2-AJY) was a sporadic patient (Fig. 1C). They received detailed ophthalmic examinations, including 
measurement of best-corrected visual acuity (BCVA) using Snellen chart, ocular alignment, slit lamp examination 
of anterior and posterior segments, and a dilated fundus examination. High-resolution spectral-domain OCT 
(Visante OCT, Carl Zeiss Meditec, Dublin, CA, USA) was used to acquire tomograms of anterior and posterior 
segments. Detailed methods have been described previously39,40. In particular, the morphology of the anterior 
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segment including iris anatomy and structure was carefully analyzed using anterior segment OCT. Foveal mor-
phology obtained from posterior segment OCT was graded using the Foveal Hypoplasia Grading Scale41.
All experiments followed the tenets of the Declaration of Helsinki, and informed consent was obtained 
after the nature and possible consequences of this study had been explained to the participants. This study was 
approved by the Institutional Review Boards of Pusan National University Yangsan Hospital.
Mutation analysis. Genomic DNA was extracted from the blood sample of each patient. Whole-exome 
sequencing (WES) was conducted using a SureSelect Focused Exome Kit (Agilent, Inc., USA). Detailed meth-
ods have been described previously42. Briefly, the qualified genomic DNA sample was randomly fragmented by 
Covaris followed by adapter ligation, purification, hybridization and PCR. Captured libraries were subjected to 
an Agilent 2100 Bioanalyzer to estimate the quality and loaded on to an Illumina HiSeq2500 (TheragenEtex Bio 
Institute, Suwon, Korea) according to the manufacturer’s recommendations. Raw image files were processed by 
HCS1.4.8 for base-calling with default parameters and sequences of each individual were generated as 100  bp 
paired-end reads.
Sequence reads were aligned to the human reference genome sequence (GRCh37.3, hg19) using the 
Burrows-Wheeler Aligner (BWA, version 0.7.12). PCR duplicate reads were marked and removed with Picard tools 
(version 1.92). Genome Analysis Toolkit (GATK, version 2.3–9) was used for indel realignment and base recalibra-
tion. Variation annotation and interpretation analysis were performed using SnpEff (version 4.2). To identify path-
ogenic mutations, 98 candidate genes associated with INS were selected based on literature reviews and Online 
Mendelian Inheritance in Man (OMIM) (see Supplementary Table S1)43,44. Variants causing non-synonymous 
amino acid changes, stop codons, insertions/deletions in coding regions, or changes to splice site sequences in 
exon/intron boundaries were identified. Common variants with minor allele frequency (MAF) > 0.01 that are 
present in dbSNP147, the Exome Aggregation Consortium (ExAC), the 1000 Genomes Project, and Korean 
Reference Genome Database (KRGDB: http://152.99.75.168/KRGDB/) were excluded. Variants screened with the 
above process were annotated for previously reported disease-causing variants using the Human Gene Mutation 
Database. Non-synonymous variants that were predicted as damaging by at least three of four prediction tools 
(SIFT, Polyphen2, LRT, MutationTaster), were considered as pathogenic mutations. These variants were confirmed 
by Sanger DNA sequencing, and screened in other family members and 150 Korean controls.
Functional analysis of PAX6 gene. Protein expression and purification. The gene encoding human 
PAX6 (residues 4–136) was amplified using PCR and inserted into a modified pETduet-1 vector, in which 
TEV protease cleavage site was included between His6-tag and PAX6 at the N-terminus. Protein production 
was carried out as previously described21, except for using Ni2+-affinity chromatography. His6 tag was removed 
by TEV protease during dialysis against buffer comprising 25 mM Tris⋅HCl, pH 7.5, 150 mM NaCl, and 5 mM 
β-mercaptoethanol (β-Me). Subsequently, protein solution was applied to a Superdex 200 16/60 column (GE 
Hralthcare) pre-equilibrated in 25 mM Hepes, pH 7.5, 150  mM NaCl, and 5  mM β-Me. Purified proteins were 
concentrated to ~10 mg/ml using a 10,000 NMWL Amicon Ultra centrifugal filter (Millipore) and flash-frozen 
in liquid nitrogen for storage. Our mutants (p.Gly72Cys and p.Val84Alafs*8) were generated by PCR-based 
mutagenesis, and purified with the same method as described above. Previously reported missense mutations 
within the linker region between two subdomains of the PD (p.Gly64Val, p.Gly72Ser, p.Gly73Asp, p.Ser74Gly 
and p.Pro76Arg), were also generated to compare DNA binding affinity. Among them, p.Gly64Val23, p.Ser-
74Gly27, and p.Pro76Arg24 have been reported to be associated with non-aniridia phenotype, whereas patients 
with p.Gly72Ser25 and p.Gly73Asp26 variant had an abnormal iris structure.
Isothermal titration calorimetry (ITC) measurement. DNA strands known to bind to PAX6 P6B (forward: 
5′-AAGCATTTTCACGCATGAGTGCACAG; reverse: 5′-TTCTGTGCACTCATGCGTGAAAATGC), P6CON 
(forward: 5′-AAATTTTCACGCTTGAGTTCACAGCT; reverse: 5′-AGCTGTGAACTCAAGCGTGAAAATTT), 
and CD19 A-ins (forward: 5′-GAATGGGGCACTGAGGCGTGACCACCGC; reverse: 5′-GCGGTGGTCACGC 
CTCAGTGCCCCATTC) (see Supplementary Fig. S1) were chemically synthesized and purified using HPLC. 
Each strand was dissolved in buffer B and assembled into a duplex by mixing them and incubating at 95 °C for 
5  min followed by cooling down to room temperature overnight. ITC measurements were performed using a 
Microcal iTC200 instrument (Malvern) as previously described45. All experiments were carried out in the buffer 
C at 25 °C. PAX6 and its mutants (20  μM) were placed into sample cells. DNA (200  μM) was injected using a 
syringe with 20 successive additions of 2  μl for 4  s with 1000  rpm stirring. Titration curves were fitted to one set 
of sites model using Malvern software supplied with the instrument.
Data availability
The datasets generated during the current study are available from the corresponding author on reasonable 
request.
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